JP2024501453A5 - - Google Patents

Info

Publication number
JP2024501453A5
JP2024501453A5 JP2023535317A JP2023535317A JP2024501453A5 JP 2024501453 A5 JP2024501453 A5 JP 2024501453A5 JP 2023535317 A JP2023535317 A JP 2023535317A JP 2023535317 A JP2023535317 A JP 2023535317A JP 2024501453 A5 JP2024501453 A5 JP 2024501453A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
cdr
alkyldiyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023535317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024501453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062797 external-priority patent/WO2022125891A2/en
Publication of JP2024501453A publication Critical patent/JP2024501453A/ja
Publication of JP2024501453A5 publication Critical patent/JP2024501453A5/ja
Withdrawn legal-status Critical Current

Links

JP2023535317A 2020-12-11 2021-12-10 抗ceaイムノコンジュゲート、及びそれらの使用 Withdrawn JP2024501453A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124353P 2020-12-11 2020-12-11
US63/124,353 2020-12-11
PCT/US2021/062797 WO2022125891A2 (en) 2020-12-11 2021-12-10 Anti-cea immunoconjugates, and uses thereof

Publications (2)

Publication Number Publication Date
JP2024501453A JP2024501453A (ja) 2024-01-12
JP2024501453A5 true JP2024501453A5 (enExample) 2024-12-10

Family

ID=79425667

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535317A Withdrawn JP2024501453A (ja) 2020-12-11 2021-12-10 抗ceaイムノコンジュゲート、及びそれらの使用

Country Status (6)

Country Link
US (1) US20240238430A1 (enExample)
EP (1) EP4259210A2 (enExample)
JP (1) JP2024501453A (enExample)
CN (1) CN116635084A (enExample)
CA (1) CA3200051A1 (enExample)
WO (1) WO2022125891A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154318A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
JP2003531149A (ja) 2000-04-13 2003-10-21 ザ・ロツクフエラー・ユニバーシテイ 抗体由来の免疫応答の増強
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
US7273608B2 (en) 2004-03-11 2007-09-25 City Of Hope Humanized anti-CEA T84.66 antibody and uses thereof
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
JP5399712B2 (ja) 2005-12-21 2014-01-29 アムゲン リサーチ (ミュンヘン) ゲーエムベーハー 可溶性ceaに対する抵抗性を有する医薬組成物
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
BR112016014952A2 (pt) 2014-02-10 2017-09-19 Merck Patent Gmbh Inibição direcionada de tgfbeta
AU2015349878A1 (en) 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2019337654A1 (en) * 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
JP7558205B2 (ja) * 2019-06-13 2024-09-30 ボルト バイオセラピューティクス、インコーポレーテッド 高分子支持アミノベンズアピン化合物
US20200390899A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US20230293716A1 (en) * 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof

Similar Documents

Publication Publication Date Title
JP2022553702A5 (enExample)
JP2022537158A5 (enExample)
JP2023553421A5 (ja) 抗cea免疫複合体、及びその使用
JP2023524271A5 (enExample)
JP2024523453A5 (enExample)
JP2022549510A5 (enExample)
WO2023208216A9 (en) Antibody-drug conjugates and preparation methods and use thereof
JP2024521629A (ja) 抗体薬物コンジュゲート、及びその調製方法及びその使用
JP2023552792A5 (enExample)
JP2022546110A5 (enExample)
JP2024545233A5 (enExample)
JP2024501453A5 (enExample)
JP2022550851A5 (enExample)
JP2023527962A5 (enExample)
JP2022554094A5 (enExample)
JP2024509099A5 (enExample)
JP2024533356A5 (enExample)
JP2025533758A (ja) 抗体-薬物複合体並びにその調製方法及び使用
JP2023552790A5 (enExample)
JP2023552791A5 (enExample)
JP2025541673A (ja) ヘテロ環化合物並びにその製造方法及び用途
JP2025539841A5 (enExample)
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2023537940A5 (enExample)
CN120957761A (zh) 具有靶向作用的偶联物及其制备方法和用途